Patent 7037888 was granted and assigned to Acorda Therapeutics, Inc. on May, 2006 by the United States Patent and Trademark Office.
The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.